MedTrace Logo

A Study to Evaluate BMS-986511 in Adults With Major Depressive Disorder

NCT07772531 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2026-08-19

No results posted yet for this study

Summary

A Study to Evaluate BMS-986511 in Adults with Major Depressive Disorder

Conditions

Interventions

DRUG

BMS-986511

Specified dose on specified days

DRUG

Placebo

Specified dose on specified days

Sponsors & Collaborators

Principal Investigators

  • Bristol-Myers Squibb · Bristol-Myers Squibb

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-10-30
Primary Completion
2028-11-06
Completion
2028-11-06
FDA Drug
Yes

Countries

  • United States
  • Czechia

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07772531 on ClinicalTrials.gov